NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

$8.98 -0.18 (-1.97 %)
(As of 04/25/2018 06:06 AM ET)
Previous Close$9.16
Today's Range$8.85 - $9.65
52-Week Range$1.17 - $11.54
Volume594,600 shs
Average Volume2.02 million shs
Market Capitalization$631.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175

Debt

Debt-to-Equity RatioN/A
Current Ratio21.71%
Quick Ratio21.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales8,847.87
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book4.51

Profitability

EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-78,662.86%
Return on Equity-40.33%
Return on Assets-38.40%

Miscellaneous

Employees44
Outstanding Shares68,970,000

How to Become a New Pot Stock Millionaire

Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte (NASDAQ:ECYT) announced its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. The biopharmaceutical company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 40.33% and a negative net margin of 78,662.86%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the business posted ($0.26) earnings per share. View Endocyte's Earnings History.

When is Endocyte's next earnings date?

Endocyte is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Endocyte.

What price target have analysts set for ECYT?

4 brokers have issued 12-month target prices for Endocyte's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next year. View Analyst Ratings for Endocyte.

Are investors shorting Endocyte?

Endocyte saw a increase in short interest in March. As of March 15th, there was short interest totalling 4,397,809 shares, an increase of 131.5% from the February 28th total of 1,899,651 shares. Based on an average daily volume of 6,654,429 shares, the short-interest ratio is currently 0.7 days. Currently, 14.6% of the shares of the stock are sold short.

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
  • Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)
  • Ms. Katherine K. Parker, VP of HR (Age 53)
  • Dr. Alison A. Armour, Chief Medical Officer (Age 54)
  • Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)

Has Endocyte been receiving favorable news coverage?

Media coverage about ECYT stock has trended somewhat positive this week, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endocyte earned a media sentiment score of 0.12 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Endocyte?

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $8.98.

How big of a company is Endocyte?

Endocyte has a market capitalization of $631.76 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.


MarketBeat Community Rating for Endocyte (ECYT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endocyte (NASDAQ:ECYT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Endocyte in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 22.05%. The high price target for ECYT is $7.00 and the low price target for ECYT is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.502.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$7.00
Price Target Upside: 22.05% downside13.15% downside92.84% upside92.84% upside

Endocyte (NASDAQ:ECYT) Consensus Price Target History

Price Target History for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Jefferies GroupInitiated CoverageBuy -> BuyHighView Rating Details
3/9/2018Wells FargoInitiated CoverageOutperform -> OutperformHighView Rating Details
2/27/2018CowenUpgradeMarket Perform -> OutperformHighView Rating Details
10/3/2017WedbushUpgradeNeutral -> Outperform$2.00 -> $7.00HighView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Endocyte (NASDAQ:ECYT) Earnings History and Estimates Chart

Earnings by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.20)($0.20)($0.20)

Endocyte (NASDAQ ECYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.19)N/AView Earnings Details
2/26/2018Q4 2017($0.16)($0.18)$0.01 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.35)($0.55)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.19)($0.08)$15.89 million$16.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.08)($0.10)$15.34 million$16.48 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.02)($0.02)ViewN/AView Earnings Details
11/1/2012Q3 2012$0.01($0.03)ViewN/AView Earnings Details
8/2/2012Q2 2012$0.39($0.12)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.31)($0.27)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.34)($0.30)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.33)($0.36)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.27)($0.35)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.40)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Endocyte (NASDAQ:ECYT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.65%
Institutional Ownership Percentage: 29.14%
Insider Trading History for Endocyte (NASDAQ:ECYT)
Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Christopher P LeamonVPSell5,036$9.07$45,676.52143,470View SEC Filing  
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51View SEC Filing  
12/28/2017Philip S LowInsiderSell50,511$4.41$222,753.51354,050View SEC Filing  
12/1/2017Christopher P LeamonVPSell23,231$5.04$117,084.24150,579View SEC Filing  
11/13/2017Philip S LowInsiderBuy5,600$4.84$27,104.00283,005View SEC Filing  
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00206,606View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00200,999View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00200,999View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.0034,282View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.0012,722View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00200,819View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.0029,154View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.0015,722View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.0029,154View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.0017,722View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.0029,154View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endocyte (NASDAQ ECYT) News Headlines

Source:
DateHeadline
Endocyte (ECYT) Expected to Post Earnings of -$0.19 Per ShareEndocyte (ECYT) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 18 at 9:31 AM
Wedbush Equities Analysts Boost Earnings Estimates for Endocyte (ECYT)Wedbush Equities Analysts Boost Earnings Estimates for Endocyte (ECYT)
www.americanbankingnews.com - April 18 at 7:58 AM
BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is ...BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is ...
www.reuters.com - April 16 at 9:56 AM
Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting ...Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting ...
globenewswire.com - April 16 at 9:56 AM
Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 16 at 9:56 AM
Endocyte (ECYT) Earns Buy Rating from Analysts at Jefferies GroupEndocyte (ECYT) Earns Buy Rating from Analysts at Jefferies Group
www.americanbankingnews.com - April 13 at 10:37 AM
Endocyte Inc. (ECYT) Is Approaching The Highs Of The YearEndocyte Inc. (ECYT) Is Approaching The Highs Of The Year
www.nasdaq.com - April 13 at 10:16 AM
Endocyte (ECYT) Upgraded by ValuEngine to SellEndocyte (ECYT) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 12:54 PM
Endocyte (ECYT) Receives "Hold" Rating from CowenEndocyte (ECYT) Receives "Hold" Rating from Cowen
www.americanbankingnews.com - April 8 at 10:49 AM
New Analyst Coverage Puts Spotlight on 5 StocksNew Analyst Coverage Puts Spotlight on 5 Stocks
finance.yahoo.com - April 4 at 5:24 PM
Endocyte (ECYT) Upgraded to "Buy" at ValuEngineEndocyte (ECYT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 4:48 PM
Endocyte, Inc. (ECYT) Given Consensus Rating of "Buy" by AnalystsEndocyte, Inc. (ECYT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 3 at 3:08 AM
 Brokerages Expect Endocyte, Inc. (ECYT) Will Post Earnings of -$0.18 Per Share Brokerages Expect Endocyte, Inc. (ECYT) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 1 at 7:23 AM
Endocyte (ECYT) Rating Increased to Hold at Zacks Investment ResearchEndocyte (ECYT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 6:04 PM
Endocyte, Inc. (ECYT) Short Interest Up 131.5% in MarchEndocyte, Inc. (ECYT) Short Interest Up 131.5% in March
www.americanbankingnews.com - March 28 at 2:44 AM
Endocyte (ECYT) Upgraded by Cowen to "Outperform"Endocyte (ECYT) Upgraded by Cowen to "Outperform"
www.americanbankingnews.com - March 24 at 10:39 PM
Head to Head Survey: Mateon Therapeutics (MATN) vs. Endocyte (ECYT)Head to Head Survey: Mateon Therapeutics (MATN) vs. Endocyte (ECYT)
www.americanbankingnews.com - March 21 at 11:25 AM
Endocyte (ECYT) Stock Rating Upgraded by BidaskClubEndocyte (ECYT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 18 at 6:40 PM
BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its BoardBRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board
www.reuters.com - March 16 at 10:58 AM
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - March 15 at 4:09 PM
 Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.18 Earnings Per Share Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - March 15 at 5:18 AM
Insider Selling: Endocyte, Inc. (ECYT) VP Sells 5,036 Shares of StockInsider Selling: Endocyte, Inc. (ECYT) VP Sells 5,036 Shares of Stock
www.americanbankingnews.com - March 12 at 4:46 PM
Endocyte (ECYT) Now Covered by Wells Fargo & CoEndocyte (ECYT) Now Covered by Wells Fargo & Co
www.americanbankingnews.com - March 10 at 12:00 AM
Endocyte, Inc. (ECYT) Given Average Rating of "Hold" by BrokeragesEndocyte, Inc. (ECYT) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 9 at 4:52 PM
Why Endocyte Stock Is on the Move TodayWhy Endocyte Stock Is on the Move Today
finance.yahoo.com - March 8 at 4:11 PM
Endocytes Lu-PSMA-617: Will It Be Lucky This Time - Seeking AlphaEndocyte's Lu-PSMA-617: Will It Be Lucky This Time - Seeking Alpha
seekingalpha.com - March 5 at 4:18 PM
Endocyte (ECYT) Rating Increased to Hold at BidaskClubEndocyte (ECYT) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 3 at 12:00 PM
Endocyte Announces Closing of Public Offering of Common StockEndocyte Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 3 at 10:36 AM
Investors Buy High Volume of Endocyte Call Options (ECYT)Investors Buy High Volume of Endocyte Call Options (ECYT)
www.americanbankingnews.com - March 2 at 7:32 AM
Endocyte Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Endocyte Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - March 1 at 4:04 PM
Endocyte up another 7% as Cowen upgrades - Seeking AlphaEndocyte up another 7% as Cowen upgrades - Seeking Alpha
seekingalpha.com - March 1 at 4:04 PM
Endocyte Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Endocyte Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - March 1 at 4:04 PM
Endocyte, Inc. (ECYT) to Post Q1 2018 Earnings of ($0.20) Per Share, Wedbush ForecastsEndocyte, Inc. (ECYT) to Post Q1 2018 Earnings of ($0.20) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 1 at 8:36 AM
Endocyte (ECYT) Raised to Hold at ValuEngineEndocyte (ECYT) Raised to Hold at ValuEngine
www.americanbankingnews.com - February 28 at 10:48 PM
Endocyte, Inc. Expected to Earn FY2022 Earnings of ($0.06) Per Share (ECYT)Endocyte, Inc. Expected to Earn FY2022 Earnings of ($0.06) Per Share (ECYT)
www.americanbankingnews.com - February 28 at 4:51 PM
Endocyte prices stock offering at $4.20; shares up 30%Endocyte prices stock offering at $4.20; shares up 30%
seekingalpha.com - February 28 at 11:29 AM
Endocyte Announces Pricing of Public Offering of Common StockEndocyte Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 28 at 10:30 AM
Endocyte Announces Proposed Public Offering of Common StockEndocyte Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 28 at 10:30 AM
Endocyte (ECYT) Reports Supply Agreement with ITM for EndolucinBeta in Phase 3 VISION TrialEndocyte (ECYT) Reports Supply Agreement with ITM for EndolucinBeta in Phase 3 VISION Trial
www.streetinsider.com - February 27 at 10:44 AM
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
finance.yahoo.com - February 27 at 10:44 AM
Endocyte (ECYT) Issues Quarterly  Earnings Results, Misses Expectations By $0.02 EPSEndocyte (ECYT) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - February 26 at 11:18 AM
Endocyte (ECYT) Posts Wider than Expected Loss in Q4Endocyte (ECYT) Posts Wider than Expected Loss in Q4
www.zacks.com - February 26 at 10:11 AM
Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION TrialEndocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
finance.yahoo.com - February 26 at 10:11 AM
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial ResultsEndocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - February 26 at 10:11 AM
Endocyte net loss improves in Q4Endocyte net loss improves in Q4
seekingalpha.com - February 26 at 8:26 AM
Endocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.16 Per ShareEndocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 26 at 5:14 AM
Endocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference CallEndocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
finance.yahoo.com - February 23 at 10:20 AM
Zacks Investment Research Lowers Endocyte (ECYT) to SellZacks Investment Research Lowers Endocyte (ECYT) to Sell
www.americanbankingnews.com - February 15 at 2:48 PM
Endocyte (ECYT) Stock Rating Upgraded by Zacks Investment ResearchEndocyte (ECYT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 10:12 AM
Endocyte (ECYT) Lowered to Sell at Zacks Investment ResearchEndocyte (ECYT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 1 at 11:35 AM

SEC Filings

Endocyte (NASDAQ:ECYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endocyte (NASDAQ ECYT) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.